| Vol. 14.37 – 20 September, 2022 |
| |
|
|
| Investigators determined whether MSCs and/or derived extracellular vesicles reduced knee osteoarthritis (OA) pain through influencing sensory neuron excitability in OA joints. [Arthritis & Rheumatology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists transplanted the xeno-free-induced MSCs into mouse models for bone and skeletal muscle regeneration and confirmed their regenerative potency. [NPJ Regenerative Medicine] |
|
|
|
| By characterizing non-myogenic MSC population in facioscapulohumeral muscular dystrophy patients’ muscles, researchers were able to identify signs of disease activity by muscle magnetic resonance imaging. [Cell Death & Disease] |
|
|
|
| Scientists investigated the effect of MSCs on B cell matrix responses to be incorporated into the assay matrix potency analytical system. [Stem Cells] |
|
|
|
| Investigators characterized MSC induced Regulatory B cells (iBreg) and identified specific Breg biomarkers by RNAseq. [Frontiers in Immunology] |
|
|
|
| The authors compared MSC cultures simultaneously grown under a conventional 19.95% O2 atmosphere or at 5% O2. [Cytotherapy] |
|
|
|
| Researchers determined that the expression of integrin alpha 6 (ITGA6) and ITGA6 antisense RNA correlated with the proliferation, cell size, and differentiation potential. [Frontiers in Genetics] |
| |
|
|
| Scientists found that alpinetin treatment was able to enhance osteogenic differentiation levels of human bone marrow MSCs in vitro and mouse ones in vivo as revealed by multiple osteogenic markers. [Phytotherapy Research] |
|
|
|
| Bone marrow MSCs were collected 24 h following TGF-β1 and myeloid-derived suppressor cell (MDSC) supernatant treatment for RNA sequencing and untargeted metabolomic analysis. [Cell and Tissue Research] |
|
|
|
|
|
| Scientists systematically summarize the emerging roles and detailed molecular mechanisms of MSC-derived exosomes in mediating cancer therapy resistance. [Molecular Cancer] |
|
|
|
| Investigators review the main findings regarding the MSCs isolated from the human vascular wall. [Stem Cells] |
|
|
|
|
| TRACON Pharmaceuticals, Inc. announced that the US FDA has granted fast-track designation for the development of envafolimab for patients with locally advanced, unresectable undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). [TRACON Pharmaceuticals, Inc.] |
|
|
|
|
| November 6 – 8, 2022 Seville, Spain |
|
|
|
|
|
| UC San Francisco – San Francisco, California, United States |
|
|
|
| Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| University of California Santa Cruz – Santa Cruz, California, United States |
|
|
|
| STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York City, New York, United States |
|
|
|
|